GSK’s RSV Vaccine Receives Key Recommendation for Broader Use in Adults

PUBLISHED: 17 Apr 2025 @ 18:19 | Comments (0) | More info about Fiona Craig

GSK (LSE:GSK) announced that the U.S. Advisory Committee on Immunization Practices has recommended the use of its RSV vaccine, Arexvy, for adults aged 50-59 who are at an increased risk for severe RSV disease. This recommendation follows a successful phase III trial and could potentially benefit over 13 million adults in the U.S. It represents a significant expansion from earlier approvals for older age groups. If approved, this broader use could have a substantial impact on GSK’s operations by opening up a larger market for Arexvy and providing protection to a wider segment of the population vulnerable to severe RSV outcomes.

About GSK

GSK is a global biopharmaceutical company dedicated to combining science, technology, and talent to improve the prevention and treatment of diseases. The company has a strong portfolio in specialty medicines and vaccines, with a focus on advancing medical innovations for patients worldwide.

Year-to-Date Price Performance: +1.05%
Average Daily Trading Volume: 10,152,966 shares
Technical Sentiment: Positive (Buy)
Market Capitalization: £54.56 billion

GSK’s strategic growth in specialty medicines, along with the positive recommendation for its RSV vaccine, positions the company well for long-term growth. However, ongoing challenges related to leverage and legal expenses warrant cautious monitoring for investors.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.